Posaconazole : a review of its use in the prophylaxis of invasive fungal infections

摘要: Posaconazole is a second-generation triazole antifungal agent with broad spectrum of activity that includes Aspergillus spp., Candida spp. and the Zygomycetes. In US, posaconazole oral suspension administered three times daily indicated for prophylaxis against invasive infections in patients aged > or =13 years who are at high risk developing these because immunosuppression, such as haematopoietic stem cell transplant (HSCT) recipients graft-versus-host disease (GVHD), those haematological malignancies prolonged neutropenia result chemotherapy. EU-approved prophylactic indications similar to US. provided effective fungal was generally well tolerated two large, designed trials HSCT GVHD, receiving induction-remission chemotherapy acute myeloid leukaemia (AML) myelodysplastic syndrome (MDS) expected neutropenia. It offers coverage clinically relevant pathogens potentially associated fewer drug-drug interactions than other licensed agents. Its usefulness some may be limited by lack an intravenous formulation, although one currently being developed. As agents, concerns remain regarding potential emergence resistance broad-spectrum posaconazole. Despite this, valuable emerging option use immunocompromized infections.